Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9847-9855

  Shao, Pengcheng P ^a   Ye, Feng ^a   Chakravarty, Prasun K ^a   Varughese, Deepu J ^a   Herrington, James B ^a   Dai, Ge ^a   Bugianesi, Randal M ^a   Haedo, Rodolfo J ^a   Swensen, Andrew M ^a   Warren, Vivien A ^a   Smith, McHardy M ^a   Garcia, Maria L ^a   McManus, Owen B ^a   Lyons, Kathryn A ^a   Li, Xiaohua ^a   Green, Mitchell ^a   Jochnowitz, Nina ^a   McGowan, Erin ^a   Mistry, Shruti ^a   Sun, Shu Yu ^a   Abbadie, Catherine ^a   Kaczorowski, Gregory J ^a   Duffy, Joseph L ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 [CYCLOPROPYL [[3 (TRIFLUOROMETHYL)PHENYL]SULFONYL]AMINO]PIPERIDIN 1 YL]CARBONYL]BENZAMIDE; CALCIUM CHANNEL BLOCKING AGENT; N CYCLOPROPYL 2 FLUORO N [1 [[5 FLUORO 2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 5 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 (PHENYLCARBONYL)PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [5 FLUORO 2 (METHYLSULFONYL)BENZOYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHOXY)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [5 FLUORO 2 (METHYLSULFONYL)BENZOYL]PIPERIDIN 4 YL] 4 (TRIFLUOROMETHOXY)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[2 (TRIFLUOROMETHOXY)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[3 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[3 (TRIFLUOROMETHOXY)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[4 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[4 (TRIFLUOROMETHOXY)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[5 FLUORO 2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 2 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[5 FLUORO 2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (METHYLSULFONYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[5 FLUORO 2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N CYCLOPROPYL N [1 [[5 FLUORO 2 (METHYLSULFONYL)PHENYL]CARBONYL]PIPERIDIN 4 YL] 4 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG; CACNA1B PROTEIN, MOUSE; CALCIUM CHANNEL N TYPE; CAV2.2 PROTEIN, RAT; N CYCLOPROPYL N (1 ((5 FLUORO 2 (METHYLSULFONYL)PHENYL)CARBONYL)PIPERIDIN 4 YL) 3 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N-CYCLOPROPYL-N-(1-((5-FLUORO-2-(METHYLSULFONYL)PHENYL)CARBONYL)PIPERIDIN-4-YL)-3-(TRIFLUOROMETHYL)BENZENESULFONAMIDE; PIPERIDINE DERIVATIVE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHRONIC PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HYPERALGESIA; IC 50; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; RAT; ANIMAL; CELL CULTURE; CHEMISTRY; DOG; DRUG EFFECT; INFLAMMATION; LIVER MICROSOME; METABOLISM; MOUSE MUTANT; NEURALGIA; PATCH CLAMP; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; CELLS, CULTURED; CHRONIC PAIN; DOGS; HUMANS; HYPERALGESIA; INFLAMMATION; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; NEURALGIA; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 84869994300     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301056k     Document Type: Article

References (30)

1. Chen, H. P.; Lamer, T. J.; Rho, R. H.; Marshall, K. A.; Sitzman, B. T.; Ghazi, S. M.; Brewer, R. P. Contemporary Management of Neuropathic Pain for the Primary Care Physician Mayo Clinic Proc. 2004, 79, 1533-1545
2. Kress, H. G.; Simpson, K. H.; Marchettini, P.; Ver Donck, A.; Varrassi, G. Intrathecal Therapy: What Has Changed With the Introduction of Ziconotide Pain Practice 2009, 9, 338-347
3. 2+ Channels to Nociceptive Transmission in Rat Spinal Laminal Neurons Eur. J. Neurosci. 2004, 19, 103-111
4. Williams, M. E.; Brust, P. F.; Feldman, D. H.; Patthi, S.; Simerson, S.; Maroufi, A.; Mccue, A. F.; Velicelebi, G.; Ellis, S. B.; Harpold, M. M. Structure and Functional Expression of An Omega-Conotoxin Sensitive Human N-Type Calcium-Channel Science 1992, 257, 389-395
5. Winquist, R. J.; Pan, J. Q.; Gribkoff, V. K. Use-Dependent Blockade of Cav2.2 Voltage-Gated Calcium Channels for Neuropathic Pain Biochem. Pharmacol. 2005, 70, 489-499
6. 2+ Channels in the Rat Spinal Cord Following Chronic Constrictive Nerve Injury Exp. Brain Res. 2002, 147, 456-463
7. Abbadie, C.; McManus, O. B.; Sun, S. Y.; Bugianesi, R. M.; Dai, G.; Haedo, R. J.; Herrington, J. B.; Kaczoroski, G. J.; Smith, M. M.; Swensen, A. M.; Warren, V. A.; Williams, B.; Arneric, S. P.; Eduljee, C.; Snutch, T. P.; Tringham, E. W.; Jochnowitz, N.; Liang, A.; MacIntyre, E.; McGowan, E.; Mistry, S.; White, V. V.; Hoyt, S. B.; London, C.; Lyons, K. A.; Bunting, P. B.; Volksdorf, S.; Duffy, J. L. Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependant Cav2 Calcium Channel B locker J. Pharmacol. Exp. Ther. 2010, 334, 545-555
8. Scott, D. A.; Wright, C. E.; Angus, J. A. Actions of Intrathecal Omega-Conotoxins CVID, GVIA, MVIIA, and Morphine in Acute and Neuropathic Pain in the Rat Eur. J. Pharmacol. 2002, 451, 279-286
9. 2+ Channels with Gene-Knockout Models. In Voltage-Gated Calcium Channels; Zamponi, G. W., Ed.; Springer-Verlag: New York, 2005; pp 346-372.
10. 2+ Channel EMBO J. 2001, 20, 2349-2356
11. Schmidtko, A.; Lotsch, J.; Freynhagen, R.; Geisslinger, G. Ziconotide for Treatment of Severe Chronic Pain Lancet 2010, 375, 1569-1577
12. Feng, Z. P.; Doering, C. J.; Winkfein, R. J.; Beedle, A. M.; Spafford, J. D.; Zamponi, G. W. Determinants of Inhibition of Transiently Expressed Voltage-Gated Calcium Channels by Omega-Conotoxins GVIA and MVIIA J. Biol. Chem. 2003, 278, 20171-20178
13. Rauck, R. L.; Wallace, M. S.; Leong, M. S.; MineHart, M.; Webster, L. R.; Charapata, S. G.; Abraham, J. E.; Buffington, D. E.; Ellis, D.; Kartzinel, R. A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain J. Pain Symptom Manage. 2006, 31, 393-406
14. Snutch, T. P. Targeting Chronic and Neuropathic Pain: The N-type Calcium Channel Comes of Age NeuroRx 2005, 4, 662-670
15. Tyagarajan, S.; Chakravarty, P. K.; Park, M.; Zhou, B. S.; Herrington, J. B.; Ratliff, K.; Bugianesi, R. M.; Williams, B.; Haedo, R. J.; Swensen, A. M.; Warren, V. A.; Smith, M.; Garcia, M.; Kaczorowski, G. J.; McManus, O. B.; Lyons, K. A.; Li, X. H.; Madeira, M.; Karanam, B.; Green, M.; Forrest, M. J.; Abbadie, C.; McGowan, E.; Mistry, S.; Jochnowitz, N.; Duffy, J. L. A Potent and Selective Indole N-Type Calcium Channel (Cav2.2) Blocker for the Treatment of Pain Bioorg. Med. Chem. Lett. 2011, 21, 869-873
16. Barrow, J. C.; Duffy, J. L. Voltage-Gated Calcium Channel Antagonists for the Central Nervous System. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: New York, 2010; Vol. 45, pp 2-18.
17. Yamamoto, T.; Takahara, A. Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke Curr. Top. Med. Chem. 2009, 9, 377-395
18. Chakravarty, P. K.; Shao, P. P.; Ye, F. New Substituted Piperidines are N-Type Calcium Channel Blockers-Useful for the Prevention and Treatment of Chronic and Neuropathic Pain. WO2007075524. July 5, 2007.
19. Chen, Z.; Islam, K.; Shao, B.; Yao, J.; Zhou, X.; Kyle, D. J. Preparation of Azetidinyl, Pyrrolidinyl, Piperidinyl, and Hexahydroazepinyl Benzenesulfonamides as N-Type Calcium Channel Blockers. WO2007110449A1, October 4, 2007.
20. Benjamin, E. R.; Chen, Z.; Sha, D.; Tafesse, L.; Victory, S. F.; Whitehead, J. W. F.; Zhou, X. Piperidinyl Compounds and Their Preparation, Pharmaceutical Compositions, and Use as N-Type Calcium Channel Modulators or Blockers for Treatment or Prevention of Pain. WO2006040181A2, March 20, 2006.
21. Yao, J.; Shao, B.; Kyle, D. J.; Sha, D.; Chen, Z.; Islam, K.; Zhou, X. Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels and Their Preparation and Use in the Treatment of Pain. WO2007118853A1, October 25, 2007.
22. Matsumura, A.; Mikamiyama, H.; Tsuno, N.; Yao, J.; Shao, B. Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels and Their Preparation and Use in the Treatment of Pain. WO2007118854A1, October 25, 2007.
23. Dai, G.; Haedo, R. J.; Warren, V. A.; Ratliff, K. S.; Bugianesi, R. M.; Rush, A.; Williams, M. E.; Herrington, J.; Smith, M. M.; McManus, O. B.; Swensen, A. M. A High-Throughput Assay for Evaluating State Dependence and Subtype Selectivity of Cav2 Calcium Channel Inhibitors Assay Drug Dev. Technol. 2008, 6, 195-212
24. Schmalhofer, W. A.; Swensen, A. M.; Thomas, B. S.; Felix, J. P.; Haedo, R. J.; Solly, K.; Kiss, L.; Kaczorowski, G. J.; Garcia, M. L. A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-a-go-go Related Gene Potassium Channel Assay Drug Dev. Technol. 2010, 8, 714-726
25. + Channel. A Model for Bad Behavior J. Med. Chem. 2003, 46, 2017-2022
26. Aronov, M. M. Predictive in Silico Modeling for hERG Channel Blockers Drug Discovery Today 2005, 10, 149-155
27. Colpaert, F. C. Evidence That Adjuvant Arthritis in the Rat Is Associated with Chronic Pain Pain 1987, 28, 201-222
28. Kim, S. H.; Chung, J. M. An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat Pain 1992, 50, 355-363
29. Kim, C.; Jun, K.; Lee, T.; Kim, S. S.; McEnery, M. W.; Chin, H.; Kim, H. L.; Park, J. M.; Kim, D. K.; Jung, S. J.; Kim, J.; Shin, H. S. Altered Nociceptive Response in Mice Deficient in the Alpha(1B) Subunit of the Voltage-Dependent Calcium Channel Mol. Cell Neurosci. 2001, 18, 235-245
30. Gang, L.; Thomas, G.; Liang-Shang, G.; Humphreys, W. G. CYP3A4 Induction by Xenobiotics: Biochemistry, Experimental Methods and Impact on Drug Discovery and Development Curr. Drug Metab. 2004, 5, 483-505